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An increased risk of posttransplant malignancy has been consistently reported following various solid organ
transplants. The malignancies most commonly encountered are non-melanoma skin cancers, carcinomas of lung or
breast and posttransplant lymphoproliferative disorders. Angiosarcoma, an uncommon vascular mesenchymal
neoplasm, is rare in the posttransplant setting. This report describes two patients who developed high-grade
angiosarcoma following a solid organ transplant. Notably, in both patients, the diagnosis of angiosarcoma was
preceded by diagnosis of a lymphoproliferative disorder with monoclonal immunoglobulin heavy chain rearrangement.
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An increased risk of developing malignancy has been
observed following solid organ transplantation, with rates
and malignancy type closely related to the transplanted
organ. The most common neoplasms encountered are
non-melanoma skin cancers (NMSC). Significant increases
in incidence of other common malignancies such as lung,
breast, and renal cell carcinomas are consistently reported
as well [1]. While posttransplant lymphoproliferative dis-
order (PTLD) is one of the more common malignancies de-
veloping in solid organ transplant recipient, angiosarcoma
is rare in this setting. We describe two patients diagnosed
with concomitant PTLD and angiosarcoma following solid
organ transplant.Case I
62-year-old man with alcoholic cirrhosis initially treated
with chemoembolization for hepatocellular carcinoma. He
underwent orthotopic liver transplant in January 2006. Fol-
lowing transplant, he was maintained on the immunosup-
pressant tacrolimus. A routine surveillance MRI performed
two years later (April 2008) revealed a 3.5 cm left adrenal
mass. Systemic imaging, including PET/CT, reported an
adrenal mass, splenomegaly (18 cm) and FDG-avid mesen-
teric and para-aortic lymphadenopathy. Biopsy of the left* Correspondence: kk2693@cumc.columbia.edu
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unless otherwise stated.adrenal mass showed a post-transplant lymphoproliferative
disorder (PTLD), consistent with an Epstein-Barr virus
(EBV) negative, monomorphic, diffuse large B-cell lymph-
oma. Spinal fluid and bone marrow were both unremark-
able. EBV DNA was undetectable by PCR. The tacrolimus
dose was decreased by half, and the patient was started on
CHOP chemotherapy (cyclophosphamide, doxorubicin,
vincristine and prednisone) with rituximab. Interim evalu-
ation with a PET/CT showed disease progression and
treatment was switched to the ICE regimen (ifosfamide,
carboplatin and etoposide) with rituximab. Autologous
stem cells were harvested and stored after his ICE chemo-
therapy. Upon completion of chemotherapy, PET/CT
demonstrated disease remission and bone marrow biopsy
remained negative for lymphoma. Five months later, the
patient developed a firm swelling of his upper lip. A
biopsy revealed monophasic diffuse large-B-cell lymph-
oma with clonal heavy chain rearrangement. A PET/CT
showed FDG avidity in the upper lip and sub-mandibular
lymph node. Due to concern for significant local morbid-
ity, he was treated with dexamethasone and a palliative
course of radiation. In view of limited improvement, the
radiation was discontinued after only four fractions. He
then received 2 additional cycles of ICE with rituximab. In
April 2009, the patient was admitted for autologous stem
cell transplant, following etoposide, carboplatin and thio-
tepa conditioning. He tolerated the autologous transplant
well, but a subsequent PET/CT showed continued FDG
avidity in the upper lip. Local radiation therapy was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tained on rituximab every three months, the last of which
was given in November 2010.
In February 2011, he presented with dyspnea on minimal
exertion, abdominal dissension, malignant ascites, and
disseminated intravascular coagulation. Imaging revealed a
cirrhotic liver, portal hypertension, and a new 23 cm hep-
atic mass with hemoperitoneum. Biopsy of the liver mass
revealed highly atypical cells with hyperchromasia and
markedly pleomorphic nuclei with prominent nucleoli and
markedly increased mitotic activity including atypical mi-
totic figures (Figure 1A). Immunohistochemical assessment
revealed tumor cells to be positive for CD31 (Figure 1B)
and focally positive for CD34, suggestive of high-grade
angiosarcoma. The cells were negative for hepatocellular
specific antigen and Human Herpes virus 8 (HHV-8). EBV
DNA was undetectable by PCR. His hospital stay was
further complicated by respiratory failure and renal failure
requiring initiation of dialysis. The patient passed away
prior to initiation of systemic therapy.
Case II
A 25-year-old female with a prolonged history of gastropar-
esis secondary to intestinal neuronal dysplasia. After
presenting with intestinal pseudo-obstruction in May 2006,
she underwent multiple surgical interventions, including aFigure 1 Histopathology of patients with angiosarcoma in the setting of
of the liver showing inter-anastomosing channels with papillary formation lined
angiosarcoma 400X CD31: Immunohistochemical stain against CD31(endothelia
of this angiosarcoma (400X). C) KM angiosarcoma 200X: A high grade angiosarc
multiple mitotic figures with scattered red blood cells but without evidence of
against CD31 (endothelial marker) demonstrates with brown staining the neoplpartial colectomy, lysis of adhesions, resection of ilieo-colic
anastomosis, and repeat ilieo-colic anastomosis. In March
2009, she presented with intestinal dysmotility and liver
failure, ultimately undergoing multi-visceral transplantation
(en bloc transplant of stomach, pancreas, liver, small bowel,
and colon). Following the transplant, she was maintained on
rapamycin for immunosuppression. EBV DNA copies were
not detected prior to transplant but quickly rose to 3,500
copies following transplant and upon initiation of immune
suppression. Her viral level became undetectable on anti-
viral therapy.
In September 2012, she had a colostomy surgery due to
abdominal distention and colonic dysmotility. At the same
time, an enlarged left cervical node was noted, and a bi-
opsy was performed. Pathology review of the specimen
showed a focal increase in large B cell population, found
to be distributed in loose nodules concerning for PTLD.
Flow cytometry was attempted but failed due to the low
cellularity of the specimen. However, a clonal immuno-
globulin heavy chain gene rearrangement was detected
by PCR, further supporting the possibility of PTLD. In
November 2012, the patient noted rapidly increasing ab-
dominal girth. CT imaging demonstrated ascites and a
4.8cm ill-defined soft tissue density in the left suprarenal
area. In January 2013, she underwent resection of the left
adrenal mass, a mass around the splenic bed, and ofsolid organ transplant. A) CM angiosarcoma 200x: Needle core biopsy
by atypical endothelial cells typical of angiosarcoma (200X). B) CM
l marker) demonstrates with brown staining the neoplastic endothelial cells
oma composed of cellular spindle malignancy growing in fascicles with
vascular formation (200X). D) KM CD31 400X: Immunohistochemical stain
astic endothelial cells of this high-grade angiosarcoma (400X).
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high-grade angiosarcoma with positive surgical margins
(Figure 1C). Immunohistochemical stains were positive for
CD34, CD31 (Figure 1D), CAN5.2, factor VIII, c-KIT and
inhibin. HHV-8 immunostaining of the tumor was negative.
Post-surgical CT scan on 2/2013 showed no evidence of re-
sidual disease. The hospital course was further complicated
by rejection, treated with anti-thymocyte globulins (ATG)
and steroids. Her condition continued to worsen with
dyspnea and new inferior vena caval and peroneal venous
thrombosis. The patient and family opted for palliative care,
and she passed away prior to systemic therapy.
Conclusions
An increased risk of developing malignancy has been
consistently observed following solid organ transplant-
ation, with rates and malignancy type varying on the trans-
planted organ [1]. Non-melanoma skin cancers (NMSCs)
are the most common malignancy in transplant recipients
and affect up to 10-45% of transplant recipients, depend-
ing on race and ultraviolet light exposure [1]. Squamous
cell carcinoma is the most common NMSC. Recipients of
renal transplants, the most common solid organ to be
transplanted, are the best studied to date in the context of
post-transplant malignancies. In renal transplant recipi-
ents, the incidences of the most common cancers (colon,
lung, prostate and breast) are roughly two-fold higher
in the first 3 years after kidney transplantation, when
compared to the general population [2]. Kaposi’s sarcoma
and non-Hodgkin’s lymphoma are more than 20-fold
higher than in the general population. When compared
to patients on transplant waiting lists, several malig-
nancies rates are more common: NMSCs (2.6-fold),
melanoma (2.2-fold), Kaposi’s sarcoma (9.0-fold) and
non-Hodgkin’s lymphoma (3.3-fold). Angiosarcoma is
not reported as a unique entity in these studies and is in-
cluded in the non-skin malignancies not otherwise speci-
fied (NOS) category which accounts for about 3% of the
malignancies developing in the first 3 years following kid-
ney transplant.
The relative rate of each post-transplant malignancy
varies depending on the transplanted solid organ. In
2011, the U.S. Organ Procurement and Transplantation
Network and the Scientific Registry of Transplant Recip-
ients reported a 2% incidence of PTLD at 5 years post
renal-transplant in EBV-negative adult recipients [3].
Following liver transplant, the rate of PTLD is 10.2% at
5 years, with slightly higher rates in EBV-negative recipi-
ents. In contrast, PTLD following heart transplant is rela-
tively infrequent in adult recipients and closely linked to
EBV status. Risk of malignancy of any kind is especially
high following lung transplant and has been reported to
be as high as 15.4% at 5 years post-transplant. These
observed differences in risk may be due to variations inlength and type of immunosuppression given to recipients
of the various solid organs.
Immunosuppression is often cited as the etiology of
the increased risk of malignancy, possibly by conferring
susceptibility to viruses implicated in oncogenesis such as
EBV, herpes simplex, herpes zoster, HHV8 and polyoma
virus [4]. Other potential mechanisms include direct onco-
genesis by the immunosuppressive agents themselves; for
example, the chromosome breaks and nuclear abnormal-
ities observed with azathioprine use [5]. Hepatic angiosar-
coma developing following an extensive cyclophosphamide
exposure was reported in a patient treated for polyarteritis
nodosa [6]. In kidney transplant recipients, immunosup-
pression with cyclosporine did not confer added risk when
compared with azathioprine/steroid treatment, whereas
treatment with tacrolimus has been shown to increase the
risk approximately two-fold. Induction or anti-rejection
therapy with OKT3 or ATG increases the risk of lymph-
oma during the first post-transplant year [7].
Sarcomas are uncommon mesenchymal malignancies
and comprise less than 1% of malignant neoplasms in
adults. 80% of them arise in soft tissues [8,9]. Angiosar-
coma is an uncommon type of soft tissue sarcoma,
which may rise in a variety of tissues or organs. A well-
documented risk factor for developing angiosarcoma is
therapeutic radiation, such as the risk observed 8–10
years after breast radiotherapy [10]. Angiosarcoma has a
propensity for early metastases and often presents with
an aggressive biologic behavior. In a series of 67 patients
with angiosarcomas, the actuarial 5 year disease-free-
survival is 35% and the 5 year overall survival is 24% [8].
In another series of 82 patients with angiosarcoma, the
five-year disease-specific survival is found to be 60%,
with negative prognostic variables including higher tumor
grade and tumors arising in areas of lymphedema or prior
irradiation [9]. Similar to the majority of soft tissue sarco-
mas, the mainstay of therapy is complete surgical resec-
tion of the tumor, if operable. Adjuvant therapies such as
post-operative radiation to the tumor bed with wide mar-
gins are offered to patients with tumors larger than 5cm
or to those with positive surgical margins [11]. The role of
adjuvant chemotherapy remains controversial in soft tis-
sue sarcoma due to lack of consistent survival benefit in
studies published to date [12]. Newer studies evaluating
paclitaxel and bevacizumab in patients with unresectable
or metastatic angiosarcoma suggest a possible role for
these to treat angiosarcoma [13,14].
Post-transplant angiosarcomas are rare and, to date,
have been reported in less than 20 solid organ transplant
recipients. In a single-institution prospective database
encompassing 1,570 liver transplantations in 1,421 pa-
tients from 1985 to 1999, 125 patients (8.8%) developed
de novo tumors, one of them being angiosarcoma [15].
The majority of reported patients with post-transplant
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tumor frequently developing at the site of a previously
placed arterio-venous fistula [16]. An association has
been suggested between angiosarcoma and oncoviruses,
such as HHV-8, following detection of a viral sequence
in the DNA of a primary angiosarcoma [17]. This associ-
ation remains controversial, as others have failed to
detect similar sequences in either primary [18] or in post-
transplant angiosarcoma [19]. In a series of 3 patients with
PTLD reported by Webster et al., 2 of the patients have
PTLD as well as angiosarcoma [16]. In this series, 1 pa-
tient has been identified with an EBV-positive tumor
and a second with an elevated EBV titer at the time of
diagnosis of disseminated angiosarcoma. The 2 patients
in our paper both had angiosarcomas diagnosed fol-
lowing a prior diagnosis of PTLD, and 1 had a posi-
tive EBV titer detected at the time of angiosarcoma
diagnosis. Both angiosarcomas were found to be negative
for HHV-8 immunostaining.
In summary, the few reported patients with angiosar-
coma and PTLD vary in type of transplanted organ, im-
munosuppression therapy and in seropositivity for a
possible oncogenic virus. While the possible association of
the rare post-transplant angiosarcomas with PTLD may
suggest the presence of underlying host variables predis-
posing the recipients to develop post-transplant malignan-
cies, these are yet to be defined. Assessment of genetic
abnormalities in these tumors in the future may inform
the possible susceptibility conferring host variables.
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